When Nvidia Corp (NVDA) backs an AI startup, the size of the check usually steals the show. But for Generate Biomedicines, the chipmaker's most valuable contribution isn't the money. It's the brainpower.
That's the word from Gevorg Grigoryan, co-founder and CTO of Generate Biomedicines, who says the relationship has grown into something far deeper than a typical investor-portfolio company arrangement.
"NVIDIA has unique vantage point on the evolution of computing in general, as well as deep expertise in accelerated computing, from GPU architecture to the highly optimized software and custom kernels that extract the greatest possible performance from it," Grigoryan told MarketDash via email.
That expertise, he added, has created "valuable technical exchange around our demanding biological workloads and how we can run them more efficiently and at greater scale."
Rather than simply writing a check, Nvidia is helping Generate tackle one of AI drug discovery's thorniest problems: running the computationally intense models that generate, evaluate, and refine potential medicines without burning through time and resources.
Why Computing Expertise Matters in AI Drug Discovery
Generate's platform leans on AI at every stage of drug development, from designing new molecules and assessing therapeutic ideas to learning from experimental data and shaping clinical plans.
According to Grigoryan, getting real value from that approach takes more than just having powerful hardware on hand. It also depends on making complex biological workloads run as efficiently as possible.
That's where Nvidia's deep experience in GPU architecture, accelerated computing, and performance tuning becomes strategically important as Generate scales its AI platform. The collaboration reflects a broader shift across the AI industry, where infrastructure providers are increasingly pairing engineering know-how with capital.
Investment Takeaway
Grigoryan's comments suggest Nvidia's influence in artificial intelligence extends well beyond supplying chips or cutting investment checks.
As AI becomes more deeply woven into industries like biotech, Nvidia's expertise in accelerated computing and software optimization is emerging as another way it supports customers and portfolio companies.
For investors, that points to Nvidia's expanding role as a technology partner helping companies build and scale AI applications, not just the hardware underneath them.
